Balaji Amines Second Quarter 2025 Earnings: EPS: ₹12.65 (vs ₹10.71 in 2Q 2024)
Balaji Amines (NSE:BALAMINES) Second Quarter 2025 Results
Key Financial Results
- Revenue: ₹3.56b (down 6.4% from 2Q 2024).
- Net income: ₹409.8m (up 18% from 2Q 2024).
- Profit margin: 12% (up from 9.1% in 2Q 2024). The increase in margin was driven by lower expenses.
- EPS: ₹12.65 (up from ₹10.71 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Balaji Amines Earnings Insights
Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India.
Performance of the Indian Chemicals industry.
The company's shares are down 2.0% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Balaji Amines' balance sheet health.
Valuation is complex, but we're here to simplify it.
Discover if Balaji Amines might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:BALAMINES
Balaji Amines
Engages in the manufacture and sale of methylamines, ethylamines, and derivatives of specialty chemicals and pharma excipients in India.
Flawless balance sheet established dividend payer.